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Objective and hypothesis: To evaluate the effectiveness of three commercial ELISA rapid tests 
in comparison with qPCR for the diagnosis of canine parvovirus infection using fecal sample. It 
was hypothesized that the ELISA rapid tests evaluated in this study are as effective as qPCR 
method in diagnosis of canine parvovirus infection in fecal samples. 
Background: Canine parvovirus-2 (CPV-2) infection is an acute, life-threatening, and highly 
contagious viral disease. The infected dogs shed virus in their stool and a variety of diagnostic 
methods have been developed for the diagnosis of the infection using fecal samples. Rapid ELISA 
tests are commonly used in veterinary practices. However, the accuracy of the results of rapid 
tests has been questioned in many reports and a low sensitivity has been reported for these tests. 
Methods: The effectiveness of three parvovirus commercial ELISA rapid tests (Zoetis, Abaxis, 
and IDEXX) was compared with the laboratory method, qPCR, as a quantitative assay with high 
sensitivity and specificity. Using qPCR allows quantitation of the amount of viral target gene in a 
sample.  Fecal samples from 80 dogs suspected of having CPV-2 infection, based on the clinical 
signs, were tested by the three ELISA rapid tests and qPCR method for the presence of canine 
parvovirus viral DNA, Specificity, sensitivity, positive, and negative predictive values (PPV and 
NPV) for all tests were calculated and compared. 
Results: A total of 42 samples qualified for testing based on the inclusion criteria. The results of 
qPCR indicated 22 positive samples; however, only 10 of those samples were diagnosed as 
positive when ELISA kits were used. There was no difference between the results of the three 
ELISA tests from different manufacturers included in the study. The ct-values for the qPCR tests 
ranged from 12.03 to 34.21. The ct- values for the samples that were found as false negatives 
when ELISA tests were used ranged from 21.12 to 34.21. The sensitivity and specificity of the 
ELISA tests were 45.4% and 100% respectively versus 100% sensitivity and specificity for the 
gold standard qPCR method. The PPV and NPV values for ELISA tests were 100% and 62.5%, 
respectively. Conclusion: ELISA rapid tests are associated with a low sensitivity and therefore, 
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INTRODUCTION AND GENERAL INFORMATION 
Introduction to canine parvovirus 
Canine parvovirus (CPV) is the main etiological agent of viral enteritis and the cause of a life-
threatening infection and highly contagious viral disease with mortality of 91% that mainly 
affects dogs. This disease is known as one of the most common causes of severe hemorrhagic 
diarrhea in puppies and young dogs. It occasionally causes myocarditis in puppies between 6-16 
weeks old, however, older animals are sometimes also affected (Kaur G et al., 2014; Nandi S et 
al., 2010; Prittie J et al., 2004). Therefore, a quick and safe diagnostic test is crucial to provide 
immediate treatment and to prevent viral spread, particularly in high population facilities such as 
animal shelters (Nandi S et al, 2010). A variety of ELISA rapid tests are currently in use for 
diagnosis of CPV infection in puppies. The ease of the procedure and the low cost of the 
operation compared to laboratory methods such as PCR, has made these rapid tests very popular 
among veterinarians and animal owners (Esfandiari J et al., 2000). However, low sensitivity and 
a high number of false negative ELISA results can lead to underdiagnoses of CPV infection, and 
therefore, higher risk for the spread of the disease (Desario C et al., 2005; Schmitz S et al., 2009; 
Proksch AL et al., 2015). On the other hand, advantages of PCR techniques, include the 
possibility for testing of several samples at the same time with higher sensitivity and specificity. 
However, testing animals within 3 to 10 days after vaccination with modified-live vaccine, may 
yield false-positive results, even if a PCR technology is used (Faz M et al., 2017). Therefore, in 
this study, samples from animals with a history of vaccination within two weeks from sampling 
were excluded.   
History 
Parvovirus CPV2 causes a disease that first emerged among dogs almost three decades ago, in 
Europe in the late 1960s. It spread worldwide and caused an epidemic of myocarditis and 
gastroenteritis in 1978 killing thousands of dogs and possibly infecting millions more.  Canine 
parvovirus is closely related to a virus that has been known since the 1920s called feline 
panleukopenia virus (FPV) which infect cats and mink and other animals (Parvoviridae, 





CPV most likely arose as the result of 2 or 3 genetic mutations in FPV that allowed it to increase 
its host range to infect dogs (Carmichael LE., 2005). 
Canine Parvovirus Taxonomy 
Canine Parvovirus is a member of the family of Parvoviridae, divided into two subfamilies: 
the Parvovirinae which infect vertebrate hosts, and the Densovirinae, that infect arthropod 
hosts. The subfamily Parvovirinae contains five genera Parvovirus, Erythrovirus, Dependovirus, 
Amdovirus, and Bocavirus (Cotmore S et al., 2014; Decaro N et al., 2012).  
Canine Parvovirus Structure 
CPV is a non-enveloped, 26 nm diameter, icosahedral virus, linear, single-stranded negative 
sense DNA, and approximately 5 kb in length. This virus contains two major open reading 
frames (ORF1 and ORF2) with hairpin structures at both the 5’ and 3’ ends (Parker J, et al., 
2017; Kaur G et al., 2014). The ORF1 encodes nonstructural proteins (NS), and ORF2 encodes 
two viral proteins (VP1, VP2) that form the capsid. VP2 plays an important role in determination 
of antigenicity of CPV, as a result, mutations of VP2 are responsible for different antigenic 
variations (Kaur G et al 2014; Cho Ho-Seong et al., 2006; Phromnoi S et al., 2010). VP1 and 
VP2 proteins are translated from substitute splicing of the same mRNA (Reed A et al., 1988).  
Virus Variants: 
There are two different parvoviruses known to infect dogs. Canine parvovirus type 1 (CPV-1) or 
the canine minute virus (MVC), isolated and identified in 1967, which may cause pneumonia, 
myocarditis, enteritis, lymphadenitis in puppies aged between 5 and 21 days and neonatal death 
(Carmichael LE et al.,1994). 
The second variant is the pathogenic canine parvovirus type 2 (CPV-2), an etiologic agent of 
canine virus enteritis, was first recognized in 1978. It is one of the important pathogens of 
domestic and wild canids causing severe gastroenteritis in young dogs, especially unvaccinated 
puppies. CPV-2 attacks the rapidly dividing intestinal crypt epithelium destroys the intestinal 
barrier causing hemorrhagic enteritis with severely low white blood cell levels, due to virus 
replication in the bone marrow and often results in sepsis (Isola J et al., 2013; Nandi S et al., 
2010). CPV2 is antigenically related to other parvovirus of carnivores similar to feline 





capsid protein. It is also highly similar to raccoon parvovirus (RPV), mink enteritis virus (MEV) 
and blue fox parvovirus (BFPV) (Steinel A et al, 2001). 
The molecular classification of CPV-2 includes three variants, CPV-2a, CPV-2b and CPV-2c, all 
of which can infect young dogs of all different breeds (Parrish CR et al., 1985; Zhao Y et al., 
2013; De la Torre D et al., 2018). CPV-2b and CPV-2c have similar health prospects for dogs, 
therefore, it is not necessary to perform sequencing in order to distinguish them from each other 
(Malkovich J et al, 2012). However, results of some studies indicate that if CPV-2c infects 
vaccinated dogs, it causes more severe disease but this difference may not be detected by 











Canine Parvovirus Infection  
 Canine parvovirus viral infection is highly contagious disease with high mortality and mortality 
of 10% (adult dogs) to 91% (unvaccinated puppies) (Nandi S et al., 2010; Appel MJ et al., 1979). 
Gastroenteritis is the main clinical sign of the disease combined with lymphopenia and 
neutropenia due to damage to the hematopoietic progenitor cells in the bone marrow and 
lymphopoietic tissues (Mylonakis M et al,. 2016).    
Pathophysiology 
Canine parvovirus most likely resulted from genetic mutations in the capsid gene of feline 
panleukopenia virus (FPV) and consequently expanded its host range to infect dogs (Ohshima T 
et al., 2009). This virus particularly infects and extinguishes rapidly dividing cells such as 
lymphopoietic tissue, bone marrow, and the villus epithelium of small-intestinal crypts. 
Because high levels of the virus is shed in feces 4-7 days post infection, exposure to infective 
feces is the main source of disease transmission.  (Kaur G et al., 2014;  Nandi S et al., 2010).  
Dogs more than 6 months of age and intact males develop CPV enteritis more often than intact 
female dogs (Houston DM et al., 1996). However, older dogs are occasionally affected. 
Susceptibility rises with a decrease in maternal antibody, intestinal parasitism, or enteric 
diseases such as Campylobacter, Salmonella, Giardia, and coronavirus infections. Factors such 
as a stressful environment will also increase the risk of severe infection (Mylonakis ME et al., 
2016).  
Different breeds have different susceptibility to parvovirus infection; nevertheless, with an 
unknown pathophysiology, mixed breeds are known to be less susceptible than pure breeds 
(Goddard A et al., 2010). Breeds that have been defined to be at great risk of the disease include 
Rottweilers, American Pit Bull, Doberman Pinschers, Terriers, English Springer Spaniels, and 
German Shepherds (De Cramer K et al., 2011). 
Clinical Signs 
The major clinical symptoms of canine parvovirus are generally associated with the intestinal 





malaise, vomiting, high fever (or hypothermia), and dehydration. It is worth noting that the 
absence of bloody diarrhea does not necessarily rule out CPV infection (Folitse R et al., 2018; 
Kelly D. Mitchel Merck manual, canine parvovirus). The disease is categorized by two 
noticeable clinical forms (i) enteritis in adult dogs and (ii) myocarditis in puppies. The virus can 
distress myocardial cells, which leads to acute heart failure and unexpected death in 
young puppies (Nandi S et al., 2010; Kilian E et al., 2018). Diarrhea may be seen in dogs of any 
age but appears frequently in puppies of less than 3 months of age (Nandi S et al., 2010). In 
severe cases, stool may be watery, or yellowish with blood. Dogs with enteritis show extreme 
pain and their appetite may be affected, resulting in rapid weight loss (Mylonakis M E et al., 
2016). Damage of the intestinal crypt epithelium results in epithelial necrosis, impaired 
absorptive capacity, villous atrophy, and interruption in gut barrier function which can result in 
bacterial translocation and bacteremia (Nandi S et al., 2010). In the early stage of the disease, a 
minor increase in temperature is observed but it will slowly turn to subnormal temperatures. 
(Nandi S et al., 2010).   
Transmission 
Canine parvovirus can spread in three ways: Fecal– oral route, Oro-nasal contact, and 
contaminated fomites of canine, cats, raccoons, mink, coyotes, wolves, and other wild animals. 
Moreover, a frequent cross-species transmission has been reported (Allison AB et al., 2013). 
Infected dogs shed the virus in their stool in large amounts after exposure (Kaur G et al., 2014; 
Nandi S et al., 2010; Miranda C et al., 2016), and since CPV is very stable in the environment, it 
can survive more than a year in feces and soil over extremes of heat, cold, or humidity. 
Therefore, contaminated environments can remain a source of infection for months. As a non-
enveloped virus, CPV is also very resistant to disinfectants (Nandi S et al., 2010). 
Diagnosis of Parvoviral infection 
Since this disease is extremely contagious, a fast and reliable diagnostic test is necessary to 
detect virus-shedding animals and to provide the necessary intensive care for diseased animals 
(Proksch AL et al., 2015). Another challenge in diagnosis of CPV infection is that several other 
pathogens such as rotavirus or campylobacter infections may result in the same clinical 
symptoms of parvovirus, therefore, diagnosis based on the clinical signs may be misleading 





Several methods have been developed to confirm CPV infection. Currently, six different 
laboratory tests for diagnosis of canine parvovirus type 2 (CPV-2) are available including 
immunochromatography, virus isolation, haemagglutination, enzyme-linked immunosorbent 
assay (ELISA), and polymerase chain reaction (PCR) (Desario C at al., 2005).  
Among these techniques, ELISA testing of the fecal samples to detect the CPV-2 antigen is 
considered a simple, quick, and reliable method by some reports (Kumar M et al, 2010). 
However, other conflicting reports indicate that ELISA testing is associated with a high 
percentage of false-negative results due to low viral shedding in earlier or later stages of the 
infection. In addition, this technique has reported to be associated with poor sensitivity compared 
to PCR (Proksch AL et al., 2015).  False positive ELISA results may be due to several reasons 
particularly recent vaccination with modified live vaccines. Therefore, it is recommended that 
every positive ELISA test should be verified by PCR, or additional supportive diagnostics 
(Mylonakis ME et al., 2016).  
PCR technology is known as a reliable method for diagnosis of this disease. Conventional or 
traditional PCR (cPCR) and quantitative PCR (qPCR) are the two main methods used for 
diagnostic purposes. c-PCR compares the intensity of the amplification of a specific DNA 
sequence on a gel to a size standard, called a ladder, to identify the approximate size of the DNA. 
cPCR is the most basic type of PCR  reaction. It is a semi-quantitative method that provides 
qualitative results and a post-PCR step involved for detection or visualization of the DNA. 
In this method, the results are not expressed as numbers and interpretation of the results is often 
limited to either positive or negative. In addition, cPCR is a time consuming method (3-6 hours 
versus 30 min to an hour for qPCR). The resolution in cPCR is poor and therefore the sensitivity 
of the test is low. In contrast, in qPCR, as a quantitative method, the amplified DNA is 
commonly detected with probes that contain fluorescent dyes and the amount of the fluorescence 
released during amplification has direct association with the amount of the amplified DNA. 
qPCR collects the data in the exponential growth phase with high resolutions and results are 
expressed numerically ( Staggemeier R et al., 2015; Geng Y et al., 2017; Espy M J et al., 2006). 
Therefore, the qPCR method is mostly used for quantitation of gene expression and viral 





et al., 2010; Desario C et al., 2005; Decaro N et al., 2005). In addition, with the ability to 
determine the cut-off points, q-PCR allows for differentiation between carrier animals versus 
those with active disease. Therefore, the qPCR technique is known as the sensitive, and optimal 
detection method for parvoviral infection and is considered a standard tool for both diagnostics 
and research purposes (Mackay et al, 2002).  
Treatment of Canine Parvoviral Infection 
Treatment of canine parvovirus has to be aggressive. It involves the use of broad-spectrum 
antibiotics, injectable anti-emetics and intravenous fluid therapy. Death may be the result of 
dehydration or secondary infection rather than the virus itself. Furthermore, myocarditis may 
increase the severity of the disease as it spreads quickly in the domestic dogs compared with the 
wild populations (Nandi  S et al., 2010). Systemic antibiotics such as ampicillin and cefoxitin are 
used as single treatments or in combination with enrofloxacin to prevent septicemia (Mylonakis 
M E et al., 2016). Intravenous fluid therapy is used to prevent dehydration from fluid loss 
through vomiting and diarrhea. A study has demonstrated the benefits of probiotic treatment in 
hemorrhagic diarrhea. (Arslan H et al., 2012; Ziese AL et al., 2018; Jensen AP et al., 2019) 
Vaccination against Canine Parvoviral Infection: 
The morbidity and mortality rate in unvaccinated puppies can reach up to 91% (Nandi S et al., 
2010; Parker J et al., 2017). However, currently, inactivated and modified live vaccines used to 
protect against canine parvovirus have significantly reduced the prevalence of the disease. 
Nevertheless, outbreaks still occur frequently which presumably arise in unvaccinated or under-
vaccinated puppies (Nova BW et al., 2018). Studies indicate that the majority of the animals at 
the age of 12 weeks respond to vaccines; however, colostrum may affect the response of the 
animal to vaccination. Other reasons for vaccine failure may include introduction of new 
antigenic variants and existence of maternal antibodies (Nandi S et al., 2010; Meeusen E et al., 
2007).  
Considering that canine parvovirus infection is a very contagious disease, a quick and safe 
diagnostic test is crucial to provide immediate treatment and to prevent viral spread. Therefore it 
is important to evaluate the effectiveness of the diagnostic methods for this disease, particularly 







MATERIALS AND METHODS 
Sample Collection 
A total of 80 stool samples were collected from various breeds of dogs exhibiting clinical signs 
of canine parvovirus infection (fever, anorexia, bloody stool, diarrhea, vomiting, and/or 
depression) over the course of two years (2018-2020). Dogs included in this study originated as 
referral patients to University of Tennessee Veterinary teaching hospital or from several 
veterinary clinics and animal shelters in East Tennessee. The inclusion and exclusion criteria for 
evaluating the samples are listed in Table 1. Based on these criteria, 38 samples were excluded 
due to canine parvovirus (CPV) vaccination within 2 weeks of sample collection. Forty-two dogs 
with symptoms of CPV infection that were also at least two weeks post-vaccination from the 
date of sample collection, were included in the study. All stool samples were stored at -20°C 
until analysis. 
Sample Analysis 
Analysis of the stool samples required several preparatory steps as described below:  
A) Sample screening using q-PCR 
To perform a diagnostic q-PCR, the following steps were followed: 
1) Primers and Probe Design. One pair of primers, forward and reverse, were designed 
using the Primer3 software package (Integrated DNA Technologies, Inc. San Diego, CA USA). 
These primer sequences, obtained using BLAST searches against CPV, target a 144 bp region of 
the non-structural (NS) gene that encodes a nuclear protein that is crucial for viral replication 
(Table 2). 
2) DNA Isolation. DNA was extracted from the 42 fecal samples included in this study 
according to the manufacturer’s instructions (QIAGEN, QIAamp DNA Micro Kit, Thermofisher 
Scientific Waltham, MA USA). DNA extracts from the feces of a healthy dog were used as a 
negative control. The PCR reactions included 20 µL master-mix (Ex-Taq HS master mix; Takara 
Bio Inc.), 1.5 µL of each primer, 1uL probe labeled with FAM dye with Black Hole Quencher, 





(Cepheid Smart Cycler ®, Sunnyvale CA, USA) under the following reaction parameters: Initial 
denaturation at 95°C for 120 seconds followed by 45 cycles of 95°C  for 15 seconds, annealing 
at 60°C for 30 seconds, and extension at 72°C for 30 seconds. 
B) ELISA Screening 
All 42 samples were additionally evaluated using each of three commonly-used commercial 
ELISA kits for detecting canine parvovirus, including  SNAP Parvo Test from IDEXX (IDEXX 
Laboratories, Inc. Westbrook, Maine USA),VetScan Canine Parvovirus Rapid Test form Abaxis 
(Abaxis, Inc. Company Union City CA USA) and WITNESS® Parvo Rapid Test from Zoetis 
(Zoetis Company Kalamazoo MI USA) following the manufactures instructions.  
C) DNA/Ct-Value Standard Curve Preparation 
In order to calculate the sensitivity and specificity of the ELISA tests compared to real time 
PCR, virus was cultured on CRFK (Crandall Reese Feline Kidney) cells and titered to generate a 
standard curve of DNA concentration versus Cycle threshold (Ct-value, the value at which 
fluorescence detection surpassing a threshold fluorescence value of 30 fluorescence units 
indicates template amplification). 
  1) Cell Culture. In order to prepare a cell culture to be infected with parvovirus, CRFK 
cells were cultured on Dulbecco's Modified Eagle Medium (DMEM) (Thermofisher scientific-
Gibco Pittsburgh PA USA) with 10 mL of pen/strep (100 Mg/ml Penicillin and 100 U/ml 
Streptomycin) and 50 mL of fetal bovine serum (FBS) (Thermofisher scientific-Gibco Pittsburgh, 
USA) in sterile 25 cm2 culture flasks at 37°C under 5% CO2. Cell cultures were frequently 
examined for confluency. Once 100% confluency was achieved (5-7 days from incubation), cells 
were re-suspended using 0.25% trypsin containing 2.21 mM EDTA (CorningTM, Rochester, NY 
USA). Finally, cells were suspended in freezing medium (10% DMSO in DMEM/F12) (Spectrum 
chemical & laboratory products, Gardena, CA USA) and subjected to sequential cooling at 4°C, -
20°C, and -80°C. 
         2) Virus Propagation and Isolation. For virus propagation, the preserved CRFK cells 
from the previous stage were thawed and transferred to 5 sterile cell culture flasks and incubated 
at 37°C. At 50% confluency, cells were inoculated with 200 μl of CPV dispensed through a 





,Cleves, OH USA). Cultures were observed daily for five days to monitor the cytopathic effect 
(CPE), indicated by cell rounding and/or total lysis of the monolayer (Figure 1).  Infected 
Cultures were then trypsinized and the virus was harvested on day 5 post-inoculation.  Briefly, 
the cells were lysed using three sequential freeze-thaw cycles to release the intracellular virus.  
The suspension was then centrifuged at 6000 rpm for 15 minutes at 4°C, and qPCR was 
performed on extracts of the supernatant to confirm the presence of the virus. Following 
confirmation of virus (via low Ct on qPCR), one mL aliquots of supernatant were collected and 
stored at -80°C as virus stocks. 
3) Construction of Positive Control Plasmid. DNA was extracted from aliquots of virus 
stock following the manufacturer’s protocol (QIAGEN, DNA Mini Kit), and the gene encoding 
the major non-structural protein of the virus, NS1, was amplified by PCR as described above. 
The qPCR products(ranges from base 492 to base 636 of the CPV genome) were sub-cloned into 
the TOPO-TA vector (TOPO® cloning Kit, Invitrogen USA, Inc.), a vector with covalently-
linked topoisomerase that relies on A-T complementarity for integration. This construct was then 
used to transform One Shot® Chemically Competent Escherichia coli following the 
manufacturer’s protocol. Putative transformants were plated on Luria-Bertani (LB) plates 
containing ampicillin and enzyme substrate for Lac-Z blue/white screening (imMedia TM Amp 
Blue for lacZ+   Amp, Invitrogen USA) and incubated overnight at 37°C.  After 24 hours, 
colonies were screened and transferred to LB Broth and shaken overnight at 37°C.  Plasmids 
were isolated using the Gene JET plasmid mini-prep kit (Thermofisher Scientific Company 
Baltics, UAB, Vilnius Ethuania) following the manufacturer’s protocol. The isolated plasmids 
were sequenced using M13 and T7 vector sequences flanking the putative NS1 sequence insert.   
4) Standard Curve Generation. Following sequence confirmation, a 10-fold serial 
dilution of the isolated plasmid was prepared to a 10-8 final dilution. Three replicates of each 
dilution were analyzed using qPCR as described above. The Ct-value from each triplicate was 
averaged and reported as the final Ct-Value for that dilution. The qPCR efficiency was calculated 
using efficiency, percent efficiency, and PCR efficiency equations  
Standard curve line equation 






    y = Ct value 
    m = slope 
    x = log (quantity) 
    b = intercept 
Efficiency (%) = 10^ (-1/Slope) x 100 
Data Analysis:  
The association between binary outcomes of qRCR and ELISA tests was evaluated using a Chi-
square test. Sensitivity, specificity, positive predictive values, and negative predictive values 
were calculated using the frequency tables. A receiver operating characteristic curve (ROC) was 
generated to illustrate the diagnostic ability of methods other than qPCR. A post hoc power 
analysis was conducted to confirm that the current sample size was large enough to detect the 
difference between the two methods with a power of at least 80%. Statistical significance was 
identified with a baseline p-value of 0.05. Analyses were conducted in SAS 9.4 TS1M6 for 










RESULTS AND DISCUSSION 
In this study, a total of 80 fecal samples were collected. Of those, 42 samples (~52%) with a 
known history of vaccination at least two weeks before sample collection were analyzed. Based 
on the post hoc power analysis, a minimum of 13 samples would be needed to detect the 
difference between qPCR and ELISA methods with a power of at least 80%, therefore, the 42 
samples analyzed in this study were well above the minimum number necessary.  Animal 
demographics and predominant clinical symptoms for the included animals are provided in Table 
4 and Figure 2. 
The results of qPCR and ELISA testing are presented in tables 5 and 6. Based on these results, 
there was significant difference between the results obtained by qPCR and all ELISA kits 
(p=0.0006). However, ELISA methods from the three manufacturers performed similarly and 
their results were identical. The generated ROC curves for ELISA tests resulted in an area under 
the curve (AUC) of ~ 73% (>50%), indicating that these methods have high specificity (i.e., the 
capability of identifying negative cases) but lower sensitivity (i.e., the capability of identifying 
positive cases) (Figure 4). 
A total of 22 positive samples were detected using qPCR, but ELISA testing failed to detect 12 
positive samples (54%), out of the 22 detected by qPCR. The PCR products of 12 samples with 
high ct-values were sequenced and the nucleotide sequence of the CPV gene was determined in 
all samples.  Sensitivity, specificity, positive predictive value (PPV) and negative predictive 
values for each technique are listed in Table 7.  
Based on these results, ELISA rapid testing is associated with a high specificity but lacks an 
ideal sensitivity. Poor sensitivity of ELISA rapid testing is also reported in other studies when 
compared to the PCR assay (Desario C et al., 2005; Faz M et al., 2017). 
The range of Ct-Value for the 22 positive samples using qPCR, was 12.03 to 34.21. In Figure 3, 
the positive samples detected by qPCR are shown in association with the prepared Ct-Value 
/DNA standard curve. 
The Ct-Values for the positive samples that were reported as false negatives in ELISA tests 





amounts of CPV-2 in clinical samples. The higher Ct-Value indicate the lower concentration of 
the viral antigen, therefore the results of this study clearly indicate that ELISA rapid tests fail in 
detecting the lower load of the viral antigen and result in false negative results. Based on the 
results of this study, the Ct-Value of 21.12 is, considered the cutoff point for the ELISA rapid 
tests to be accurate (Figure 5). In terms of the clinical interpretation of these results, if a positive 
ELISA test result is obtained, the diagnosis of CPV enteritis is projected to be correct. However, 
a negative ELISA test may indicate a false negative result due to a lower fecal load of CPV 
antigen resulting from milder disease, or watery diarrhea. Other causes of false negative results 
may include mutation of the CPV strain, technical issues in performing the test or sampling 
errors (Faz M et al., 2017; Proksch AL., 2015).  
In relation to the PCR technologies, though the sensitivity and specificity is ideal, if a mutated 
CPV strain is causing the disease, even the PCR method may fail in detecting true positive 
samples (Proksch AL., 2015). The use of nucleic acid–based testing is recommended to ensure 
that mutations have not occurred (Hong C et al., 2007).  
Therefore, if the PCR results of CPV testing is negative but clinical signs and hematological and 
biochemical parameters are strongly suggesting a parvoviral infection, it is imperative to 
consider other testing methods such as nucleic acid-base testing to determine a potentially 
















ELISA rapid (snap) testing is a suitable testing method only for screening, as particularly in 
lower load of the viral antigen, the sensitivity of these tests is very low which may lead to 
misdiagnosis and further increase in mortality and spread of the infection. In contrast, PCR 
technology has a high sensitivity and specificity, and therefore, the negative ELISA test results 
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Table 1:  Inclusion and Exclusion Criteria for Samples 







• Vaccination for CPV within 2 weeks before sampling  
 
 
• Diarrhea  
• Lethargy 
• Loss of appetite 
• Bloody diarrhea 
• Depression 
• Anorexia 
• High body temperature (over 103 degrees) 
• Vomiting 
• Dogs with known history of at least 2 weeks post-vaccination from 













Table 2: Primers and Probes  




  5’-GAC TGG GAA TCG GAA GTT GA 3’ 
  5’-GAA TGC CAG CCT TGA TCT TT 3’ 












































10-8 10 1 31.78 
 
10-7 100 2 29.93 
 
10-6 1000 3 27.04 
 
10-5 10000 4 24.07 
 
10-4 100000 5 21.21 
 
10-3 1000000 6 16.83 
 
10-2 10000000 7 15.15 
 





Table 4: Demographics of 42 Animals that were Included in the Study:  
Sex                        Number                                   Age 
Female 
Male 
              19(45%)                                  7 Weeks- Adult 





























































IDEXX Abaxis Zoetis 
Positive 22 10 10 10 
Negative 20 32 32 32 































Table 7: Comparing Sensitivity, Specificity, PPV, and NPV for PCR and ELISA tests performed 
on 42 fecal samples suspected of parvoviral infection.  
Testing Method   Sensitivity   Specificity       PPV      NPV 
q-PCR         100       100        100       100 
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Figure 3: DNA concentration/Ct values standard curve. The qPCR had a linear dynamic range 
between 10 8 and 101copies, with a slope of −2.908, a y-intercept of 35.36, and a mean 








































                 Figure 4: ROC curve to illustrate the diagnostic ability of the ELISA rapid  
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